SCHEMBL2968478

SCHEMBL2968478

COC(c1cccc(-n2cnc3cc(CN)ccc32)c1)c1nccs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.48
KLKB1 P03952 1/20 0.38
FGFR1 P11362 8/20 0.37
HPGD P15428 2/20 0.36
PRKDC P78527 1/20 0.36
GABRP O00591 2/20 0.36
GABRD O14764 2/20 0.36
GABRA1 P14867 2/20 0.36
GABRB1 P18505 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRA5 P31644 2/20 0.36
GABRA3 P34903 2/20 0.36
GABRA2 P47869 2/20 0.36
GABRB2 P47870 2/20 0.36
GABRA4 P48169 2/20 0.36
GABRE P78334 2/20 0.36
GABRA6 Q16445 2/20 0.36
GABRG1 Q8N1C3 2/20 0.36
GABRG3 Q99928 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2978010 0.91 ALOX5 (0.48) ALOX5FGFR1HPGDPRKDCKIT
SCHEMBL2653867 0.83 FGFR1 (0.41) KLKB1FGFR1HPGDKITFLT3
SCHEMBL2976802 0.81 GABRP (0.39) FGFR1HPGDGABRPGABRDGABRA1
SCHEMBL2652489 0.81 FGFR1 (0.39) FGFR1HPGDGABRPGABRDGABRA1
SCHEMBL2968148 0.81 ALOX5 (0.40) ALOX5FGFR1HPGDPRKDCGABRA1
SCHEMBL2977437 0.81 FGFR1 (0.48) ALOX5FGFR1HPGDGABRA1GABRG2
SCHEMBL2967387 0.79 GABRP (0.37) FGFR1HPGDGABRPGABRDGABRA1
SCHEMBL2652183 0.76 LOXL2 (0.52) FGFR1HPGDGABRPGABRDGABRA1
SCHEMBL2652227 0.74 PRKCI (0.40) FGFR1HPGDGABRPGABRDGABRA1
SCHEMBL2653977 0.73 FGFR1 (0.41) FGFR1HPGDKITFLT3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US claimed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US claimed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 ALOX5 3303/4885KLKB1 3460/4885FGFR1 4324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.